Side-by-side · Research reference
MOTS-cvsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/68 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
01Mechanism of Action
Parameter
MOTS-c
Pancragen
Primary target
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
Stress-responsive, AMPK-dependent nuclear translocationKim 2018
Yes — preserves physiological glucose-insulin response
Origin
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
—
—
02Dosage Protocols
Parameter
MOTS-c
Pancragen
Standard dose
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
—
Frequency
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Once daily for 10 daysGoncharova 2014
Lower / starter dose
2.5–5 mg / week
Recommended due to limited human data.
—
Evidence basis
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Duration
4–12 weeks (experimental)
Optimal cycle length unknown.
—
Reconstitution
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
—
Timing
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
—
Half-life
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
03Metabolic / Fat Loss Evidence
Parameter
MOTS-c
Pancragen
Primary fat target
Diet-induced / metabolic obesity; systemic fat utilization
—
Quantified reduction
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
—
IGF-1 impact
No direct IGF-1 pathway; AMPK-mediated
—
Effect on lean mass
High dose significantly ↑ lean mass in mice
—
Triglycerides
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
—
Effect reversibility
Unknown — no long-term follow-up data
—
Key publication
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
—
04Side Effects & Safety
Parameter
MOTS-c
Pancragen
Injection site reaction
Mild irritation (reported)
—
Fluid retention / Edema
Not reported
—
Cardiovascular
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
—
Cancer risk
Contradictory data — some models suggest pro-proliferative effects
—
CNS / Neurological
Insomnia, headache (anecdotal reports)
—
GI symptoms
Nausea, stomach discomfort (reported)
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
—
Evidence quality
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
Pancragen
—Relative Contraindications
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
MOTS-c
Pancragen
1. Reconstitution
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Injection site
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. Timing
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
No specific timing constraints documented. Administered once daily in primate protocols.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
5. Needle
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
—
06Stack Synergy
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction
Pancragen
— no documented stacks